Reduction of rat brain CD8+ T-cells by levodopa/benserazide treatment after experimental stroke

Eur J Neurosci. 2014 Jul;40(2):2463-70. doi: 10.1111/ejn.12598. Epub 2014 Apr 23.

Abstract

The activation of inflammatory cascades in the ischemic hemisphere impairs mechanisms of tissue reorganization with consequences for recovery of lost neurological function. Recruitment of T-cell populations to the post-ischemic brain occurs and represents a significant part of the inflammatory response. This study was conducted to investigate if treatment with levodopa, potentially acting as an immunomodulator, affects the T-cell accumulation in the post-ischemic brain. Male Sprague-Dawley rats were subjected to transient occlusion of the middle cerebral artery (tMCAO) for 105 min followed by levodopa/benserazide treatment (20 mg/kg/15 mg/kg) for 5 days initiated on day 2 post-stroke. One week after tMCAO, T-cell populations were analysed from brains, and levels of interleukin (IL)-1β, chemokine (C-X-C motif) ligand 1, IL-4, IL-5, interferon gamma and IL-13 were analysed. After levodopa/benserazide treatment, we found a significant reduction of cytotoxic T-cells (CD3+ CD8+ ) in the ischemic hemisphere together with reduced levels of T-cell-associated cytokine IL-5, while other T-cell populations (CD3+, CD3+ CD4+, CD3+ CD4+ CD25+) were unchanged compared with vehicle-treated rats. Moreover, a reduced number of cells was associated with reduced levels of intercellular adhesion molecule 1, expressed in endothelial cells, in the infarct core of levodopa/benserazide-treated animals. Together, we provide the first evidence that dopamine can act as a potential immunomodulator by attenuating inflammation in the post-ischemic brain.

Keywords: cerebral ischemia; dopamine; immunomodulation; inflammation; recovery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacology*
  • Antiparkinson Agents / therapeutic use
  • Benserazide / adverse effects
  • Benserazide / pharmacology*
  • Benserazide / therapeutic use
  • Brain / cytology
  • Brain / drug effects
  • Brain / metabolism
  • CD8-Positive T-Lymphocytes / drug effects*
  • Chemokine CXCL1 / genetics
  • Chemokine CXCL1 / metabolism
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / immunology*
  • Infarction, Middle Cerebral Artery / metabolism
  • Intercellular Adhesion Molecule-1 / genetics
  • Intercellular Adhesion Molecule-1 / metabolism
  • Interferon-gamma / genetics
  • Interferon-gamma / metabolism
  • Interleukins / genetics
  • Interleukins / metabolism
  • Levodopa / adverse effects
  • Levodopa / pharmacology*
  • Levodopa / therapeutic use
  • Male
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Antiparkinson Agents
  • Chemokine CXCL1
  • Interleukins
  • Intercellular Adhesion Molecule-1
  • Levodopa
  • Benserazide
  • Interferon-gamma